The modern U.S. biotechnology company announced a week ago that the potential new COVID-19 vaccine is 94.5% effective in protecting people from Coronavirus, according to preliminary results from late-stage clinical trials. Shortly afterwards, global doctors Pfizer and BioNTech said that the candidate for the COVID-19 vaccine is 95% effective, even in adults over 65 years of age.
‘… but we are closing an agreement with the EU Commission’
Now, Modern CEO Stephane Bancel has stated that the pharmacist will charge the government between $ 25 and $ 37 for each dose of its COVID-19 vaccine candidate, depending on the amount prescribed. “Our vaccine is therefore worth as much as a shot for the flu, which is between $ 10 and $ 50,” he told the German weekly Welt am Sonntag (WamS).
According to media reports, an EU official who took part in the talks on Monday said the European Commission wanted to reach an agreement with Modern to supply millions of doses of its vaccine candidate at a price of less than $ 25 per dose. “Nothing has been signed yet, but we are close to an agreement with the EU Commission. We want to deliver to Europe and we are conducting constructive talks,” Bancel told WamSi, adding that it is only a “day matter” until the contract is signed. be ready.
vaccine manufacturer talks indian govt
Earlier this week, ANI announced that the Government of India is in talks with the US biotech giant Moderna about the successful development of the COVID-19 vaccine candidate. “The government is in talks with domestic and international vaccine manufacturers. In addition to modern, the government is also in communication with Pfizer, Serum Institute, Bharat Biotech and Zydus Cadila about the safety, immunogenicity and effectiveness of COVID-19 vaccine candidates,” a senior government official said. .
READ Punjab farmers’ unions call for CM to lift railway blockade for 15 days
READ Amit Shah BJP-led center boosts development in Tamil Nadu ahead of 2021 elections
Meanwhile, Adar Poonawalla, director general of the Serum Institute of India (SII), said on Thursday that the Oxford COVID-19 vaccine should be available for health workers and the elderly for all citizens in February and April next year. He said it will be priced up to 1,000 euros for the two doses needed by the public, depending on the final test results and regulatory approvals.
Asked at what price the public will get, he said it will be around 5-6 USD per dose, with an MRP of around 1,000 RS for the two doses required. “It will be much cheaper for the Indian government to get a price around 3-4 USD because it will buy in large volume and gain access similar to what COVAX has achieved. We are still far more expensive and cheaper than other vaccines on the market today,” he said. du Poonawallak.
READ Modi PM emphasizes transparency and retraining in post-COVID world at G20 Summit
READ Comedian Bharti Singh was arrested by the UN after admitting to drug use
(With agency tickets)